BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Leerink Partners Reiterates Outperform Rating on BeOne Medicines (ONC)
June 27, 2025 8:51 AM EDTLeerink Partners analyst Andrew Berens reiterated an Outperform rating and $334.00 price target on BeOne Medicines (NASDAQ: ONC).
The analyst comments "Bottom Line: Yesterday, BeOne (ONC, OP) hosted an R&D Day, providing an overview of the company's R&D strategy and key development-stage... More
